Description

Additional microbiota profiling data from the GTB1 probiotic trial in IBS-D participants, comparing bacterial diversity metrics between probiotic and placebo groups. The results indicate potential shifts in microbial community structure following four weeks of supplementation.

Figure 9

Chart

Source Paper

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

Nutrients (2022)

PMID: 35631156

DOI: 10.3390/nu14102015

Cite This Figure

![Figure 9: Additional microbiota profiling data from the GTB1 probiotic trial in IBS-D participants, comparing bacterial diversity metrics between probiotic and placebo groups. The results indicate potential shifts in microbial community structure following four weeks of supplementation.]()

> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)

<figure>
  <img src="" alt="Additional microbiota profiling data from the GTB1 probiotic trial in IBS-D participants, comparing bacterial diversity metrics between probiotic and placebo groups. The results indicate potential shifts in microbial community structure following four weeks of supplementation." />
  <figcaption>Figure 9. Additional microbiota profiling data from the GTB1 probiotic trial in IBS-D participants, comparing bacterial diversity metrics between probiotic and placebo groups. The results indicate potential shifts in microbial community structure following four weeks of supplementation.<br>  Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption>
</figure>

Related Evidence

Lactobacillus plantarum for Irritable Bowel Syndrome (IBS)

Grade B · 5 studies